Immunogenicity of CRISPR Therapeutics-Critical Considerations for Clinical Translation

Overview

Journal Front Bioeng Biotechnol

Date 2023 Mar 6

PMID 36873375

Authors

Radwa Ewaisha

Karen S Anderson

Affiliations

Soon will be listed here.

Abstract

CRISPR offers new hope for many patients and promises to transform the way we think of future therapies. Ensuring safety of CRISPR therapeutics is a top priority for clinical translation and specific recommendations have been recently released by the FDA. Rapid progress in the preclinical and clinical development of CRISPR therapeutics leverages years of experience with gene therapy successes and failures. Adverse events due to immunogenicity have been a major setback that has impacted the field of gene therapy. As several CRISPR clinical trials make progress, the challenge of immunogenicity remains a significant roadblock to the clinical availability and utility of CRISPR therapeutics. In this review, we examine what is currently known about the immunogenicity of CRISPR therapeutics and discuss several considerations to mitigate immunogenicity for the design of safe and clinically translatable CRISPR therapeutics.

Citing Articles

Targeted inactivation of EWSR1 : : FLI1 gene in Ewing sarcoma via CRISPR/Cas9 driven by an Ewing-specific GGAA promoter.

Cervera S, Martinez S, Iranzo-Martinez M, Notario L, Melero-Fernandez de Mera R, Alonso J Cancer Gene Ther. 2025; .

PMID: 40089636 DOI: 10.1038/s41417-025-00887-8.

Focused ultrasound widely broadens AAV-delivered Cas9 distribution and activity.

Gumusgoz E, Kasiri S, Youssef I, Verma M, Chopra R, Villarreal Acha D Gene Ther. 2025; .

PMID: 39893321 DOI: 10.1038/s41434-025-00517-w.

Enhancing precision in cancer treatment: the role of gene therapy and immune modulation in oncology.

Youssef E, Fletcher B, Palmer D Front Med (Lausanne). 2025; 11:1527600.

PMID: 39871848 PMC: 11769984. DOI: 10.3389/fmed.2024.1527600.

2024 White Paper on Recent Issues in Bioanalysis: Evolution of Immunogenicity Assessment beyond ADA/NAb; Regulated Genomic/NGS Assays; Hypersensitivity Reactions; Minimum Noise Reduction; False Positive Range; Modernized Vaccine Approaches; NAb/TAb....

Tounekti O, Prior S, Wassmer S, Xu J, Wong A, Fang X Bioanalysis. 2025; 17(3):105-149.

PMID: 39862111 PMC: 11863570. DOI: 10.1080/17576180.2024.2439229.

Expanding Horizons of CRISPR/Cas Technology: Clinical Advancements, Therapeutic Applications, and Challenges in Gene Therapy.

Bairqdar A, Karitskaya P, Stepanov G Int J Mol Sci. 2025; 25(24.

PMID: 39769084 PMC: 11678091. DOI: 10.3390/ijms252413321.

References

Vita R, Overton J, Greenbaum J, Ponomarenko J, Clark J, Cantrell J . The immune epitope database (IEDB) 3.0. Nucleic Acids Res. 2014; 43(Database issue):D405-12. PMC: 4384014. DOI: 10.1093/nar/gku938. View

Ferdosi S, Ewaisha R, Moghadam F, Krishna S, Park J, Ebrahimkhani M . Multifunctional CRISPR-Cas9 with engineered immunosilenced human T cell epitopes. Nat Commun. 2019; 10(1):1842. PMC: 6478683. DOI: 10.1038/s41467-019-09693-x. View

Thi E, Mire C, Ursic-Bedoya R, Geisbert J, Lee A, Agans K . Marburg virus infection in nonhuman primates: Therapeutic treatment by lipid-encapsulated siRNA. Sci Transl Med. 2014; 6(250):250ra116. PMC: 4502585. DOI: 10.1126/scitranslmed.3009706. View

Senturk S, Shirole N, Nowak D, Corbo V, Pal D, Vaughan A . Rapid and tunable method to temporally control gene editing based on conditional Cas9 stabilization. Nat Commun. 2017; 8:14370. PMC: 5322564. DOI: 10.1038/ncomms14370. View

Garriga-Canut M, Agustin-Pavon C, Herrmann F, Sanchez A, Dierssen M, Fillat C . Synthetic zinc finger repressors reduce mutant huntingtin expression in the brain of R6/2 mice. Proc Natl Acad Sci U S A. 2012; 109(45):E3136-45. PMC: 3494930. DOI: 10.1073/pnas.1206506109. View

Gurumoorthy N, Nordin F, Tye G, Wan Kamarul Zaman W, Ng M . Non-Integrating Lentiviral Vectors in Clinical Applications: A Glance Through. Biomedicines. 2022; 10(1). PMC: 8773317. DOI: 10.3390/biomedicines10010107. View

Maeder M, Stefanidakis M, Wilson C, Baral R, Barrera L, Bounoutas G . Development of a gene-editing approach to restore vision loss in Leber congenital amaurosis type 10. Nat Med. 2019; 25(2):229-233. DOI: 10.1038/s41591-018-0327-9. View

Shen X, Lin Q, Liang Z, Wang J, Yang X, Liang Y . Reduction of Pre-Existing Adaptive Immune Responses Against SaCas9 in Humans Using Epitope Mapping and Identification. CRISPR J. 2022; 5(3):445-456. DOI: 10.1089/crispr.2021.0142. View

Terry L, Htun Oo Y . The Next Frontier of Regulatory T Cells: Promising Immunotherapy for Autoimmune Diseases and Organ Transplantations. Front Immunol. 2020; 11:565518. PMC: 7538686. DOI: 10.3389/fimmu.2020.565518. View

10.

Nelson C, Wu Y, Gemberling M, Oliver M, Waller M, Bohning J . Long-term evaluation of AAV-CRISPR genome editing for Duchenne muscular dystrophy. Nat Med. 2019; 25(3):427-432. PMC: 6455975. DOI: 10.1038/s41591-019-0344-3. View

11.

Toral M, Charlesworth C, Ng B, Chemudupati T, Homma S, Nakauchi H . Investigation of Cas9 antibodies in the human eye. Nat Commun. 2022; 13(1):1053. PMC: 8881612. DOI: 10.1038/s41467-022-28674-1. View

12.

Simhadri V, Hopkins L, McGill J, Duke B, Mukherjee S, Zhang K . Cas9-derived peptides presented by MHC Class II that elicit proliferation of CD4 T-cells. Nat Commun. 2021; 12(1):5090. PMC: 8384835. DOI: 10.1038/s41467-021-25414-9. View

13.

Uchida N, Drysdale C, Nassehi T, Gamer J, Yapundich M, DiNicola J . Cas9 protein delivery non-integrating lentiviral vectors for gene correction in sickle cell disease. Mol Ther Methods Clin Dev. 2021; 21:121-132. PMC: 8005818. DOI: 10.1016/j.omtm.2021.02.022. View

14.

Foust K, Nurre E, Montgomery C, Hernandez A, Chan C, Kaspar B . Intravascular AAV9 preferentially targets neonatal neurons and adult astrocytes. Nat Biotechnol. 2008; 27(1):59-65. PMC: 2895694. DOI: 10.1038/nbt.1515. View

15.

Maguire A, High K, Auricchio A, Wright J, Pierce E, Testa F . Age-dependent effects of RPE65 gene therapy for Leber's congenital amaurosis: a phase 1 dose-escalation trial. Lancet. 2009; 374(9701):1597-605. PMC: 4492302. DOI: 10.1016/S0140-6736(09)61836-5. View

16.

Chavez A, Scheiman J, Vora S, Pruitt B, Tuttle M, Iyer E . Highly efficient Cas9-mediated transcriptional programming. Nat Methods. 2015; 12(4):326-8. PMC: 4393883. DOI: 10.1038/nmeth.3312. View

17.

Gough V, Gersbach C . Immunity to Cas9 as an Obstacle to Persistent Genome Editing. Mol Ther. 2020; 28(6):1389-1391. PMC: 7264432. DOI: 10.1016/j.ymthe.2020.05.007. View

18.

Samaranch L, San Sebastian W, Kells A, Salegio E, Heller G, Bringas J . AAV9-mediated expression of a non-self protein in nonhuman primate central nervous system triggers widespread neuroinflammation driven by antigen-presenting cell transduction. Mol Ther. 2014; 22(2):329-337. PMC: 3918916. DOI: 10.1038/mt.2013.266. View

19.

Maus M, Haas A, Beatty G, Albelda S, Levine B, Liu X . T cells expressing chimeric antigen receptors can cause anaphylaxis in humans. Cancer Immunol Res. 2014; 1(1):26-31. PMC: 3888798. DOI: 10.1158/2326-6066.CIR-13-0006. View

20.

Calcedo R, Vandenberghe L, Gao G, Lin J, Wilson J . Worldwide epidemiology of neutralizing antibodies to adeno-associated viruses. J Infect Dis. 2009; 199(3):381-90. PMC: 10826927. DOI: 10.1086/595830. View